Contact:

RegeneRx:
J.J. Finkelstein
jjfnk@regenerx.com
301.280.1992
or
Financial Relations Board
Leslie Loyet
Analyst Inquiries
312.640.6672
or
Kathy Waller
General Inquiries
312.640.6696

RegeneRx Biopharmaceuticals, Inc. (AMEX: RGN), www.regenerx.com, today announced that it will hold a conference call on Tuesday, July 31, 2007, at 4:30 p.m. Eastern Time (3:30 p.m. Central Time) to provide an update on its clinical trials program and other related information.

The conference call will be accessible by telephone and through the Internet. Interested individuals are invited to access the call by dialing 800-565-5442. To participate on the webcast, log on to the company's website at www.regenerx.com or www.viavid.net 15 minutes before the call to download the necessary software.

For those unable to listen to the call live, a taped rebroadcast will be available beginning approximately two hours after completion of the live call on July 31, 2007 through August 7, 2007. To access the replay, dial 888-203-1112 and request reservation number 4195229. A replay of the call will also be available at www.regenerx.com or www.viavid.net for 30 days.

About RegeneRx Biopharmaceuticals, Inc.
RegeneRx is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Currently, RegeneRx is developing TB4, a 43 amino acid peptide, in part, under an exclusive world-wide license from the National Institutes of Health. Preliminary research suggests that TB4 may prove efficacious for multiple indications; therefore, RegeneRx is developing TB4 as the cornerstone of its therapeutic platform. The technology platform has many potential applications in both the pharmaceutical and consumer products sectors. RegeneRx holds nearly 60 world-wide patents and patent applications related to dermal, ocular, and internal wounds and tissue repair, cardiac and neurological injuries, septic shock and several consumer product areas. RegeneRx is currently sponsoring three Phase 2 chronic dermal wound healing clinical trials, a Phase 2 ophthalmic trial, and a Phase 1a cardiovascular clinical trial as part of its ongoing clinical development program.

The RegeneRx Technology Platform
TB4 is a synthetic version of a naturally occurring peptide present in virtually all human cells. It is a first-in-class drug candidate that promotes endothelial cell differentiation, angiogenesis in dermal tissues, keratinocyte migration, collagen deposition, and down-regulates inflammation. One of TB4's key mechanisms of action is its ability to regulate the cell-building protein, actin, a vital component of cell structure and movement. Of the thousands of proteins in cells, actin represents up to 10% of the total protein and, thus, plays a major role in the physiology of the cell. RegeneRx has identified several molecular variations of TB4 that may affect the aging of skin, among other properties, and could be important candidates as active ingredients in pharmaceutical and consumer products. Researchers at the National Institutes of Health, and at other academic institutions throughout the U.S., have published numerous scientific articles indicating that TB4 is effective in accelerating dermal and corneal wound healing in several animal models, under a variety of conditions. In two articles published in the scientific journal, Nature, researchers found that TB4 protects heart tissue following a myocardial infarction (heart attack) and can regenerate coronary vessels in laboratory animals. Abstracts of scientific papers related to TB4's mechanisms of action may be viewed at RegeneRx's web page: www.regenerx.com.

SOURCE: RegeneRx Biopharmaceuticals, Inc.

Back To 2007 Press Release Archives